Alector plans to present additional phase 2 data highlighting clinical & biomarker endpoints in future

Alector announces promising preliminary data from al001 phase 1b and phase 2 open-label long-term dosing study of people with frontotemporal dementia.alector inc - pivotal phase 3 study initiated in july 2020.alector -treatment with al001 in phase 2 study resulted in sustained restoration of plasma progranulin levels in ftd-grn patients back to normal range.alector - in phase 2 study, majority of symptomatic ftd-grn participants showed a decrease in plasma neurofilament light chain levels from baseline.alector inc - al001 was generally safe and well-tolerated in phase 1b study.alector - due to covid-19, several clinical sites for phase 2 study were temporarily closed or conducted reduced or remote patient assessments.alector - early data suggest longer term treatment with al001 could lead to sustained increase in pgrn & sustained reduction in plasma nfl over time.alector inc - plans to present additional phase 2 data highlighting clinical & biomarker endpoints in future.
ALEC Ratings Summary
ALEC Quant Ranking